Dr. Salani on the Role of HER2 Expression in Advanced Uterine Serous Carcinoma

Video

Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

Ritu Salani, MD, MBA, director, Division of Gynecologic Oncology, professor, Obstetrics and Gynecology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

Testing for HER2 expression has become part of the standard of care for patients with uterine serous carcinoma, according to Salani, who adds that HER2 expression can be part of a pathology report. For patients with HER2-positive disease, trastuzumab (Herceptin) is added to chemotherapy consisting of carboplatin and paclitaxel, Salani explains.

Adding a HER2-targeted agent is not a universal decision across different histologies, Salani stresses. However, the development of antibody-drug conjugates have been well tolerated and have shown activity in patients with select HER2-low cancers, Salani continues. These findings could open additional avenues of treatment for subsets of patients with HER2-positive disease in different histologies, Salani concludes.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD